Immunome, Inc. (Nasdaq: IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted ...

Immunome (NASDAQ:IMNM) shares soared about 30% after the biotech group reported encouraging topline findings from its Phase 3 ...

The pivotal phase 3 RINGSIDE trial investigated varegacestat, an oral gamma secretase inhibitor, in patients with progressing desmoid tumors.

Celecoxib improves disease-free and overall survival in ctDNA-positive stage III colon cancer patients when combined with ...

Roche has lifted the lid on the data behind its second phase 3 giredestrant win, linking the oral selective estrogen receptor ...

Domestic gardens, not all green spaces, were linked to higher melanoma and non-melanoma skin cancer risk, especially in genetically and phenotypically susceptible people, in a large prospective cohort ...

The tumour–stroma ratio (TSR) is emerging as a robust, cost‐effective histopathological parameter that quantifies the relative proportion of neoplastic cells to the surrounding stromal tissue.

At the San Antonio Breast Cancer Symposium, researchers presented findings on Clarity BCR, a multimodal multitask ...

The U.S. Food and Drug Administration has approved Pfizer's Padcev (enfortumab vedotin-ejfv), a Nectin-4 directed ...

Melanoma located on the head and neck was associated with higher risk of all-cause and cancer-specific mortality compared with tumors on the trunk.